An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
J Immunother Cancer. 2019 Mar 13;7(1):72
Oncologist. 2019 Mar 04;:
Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.
Cancer. 2019 Feb 15;:
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.
Target Oncol. 2019 Feb 11;:
Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.
Oncologist. 2019 Feb 06;:
Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck.
Clin Transl Radiat Oncol. 2019 Feb;15:13-19
Cancer Med. 2018 Dec 21;:
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.
J Clin Oncol. 2018 Dec 13;:JCO2018782276
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
Eur J Cancer. 2018 Dec 06;107:1-7
J Matern Fetal Neonatal Med. 2018 Aug 29;:1-11